review on blood stage vaccine against malarai
Post on 06-Apr-2018
218 Views
Preview:
TRANSCRIPT
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
1/14
REVIEW
The future for blood-stage vaccines against malaria
Jack S Richards and James G Beeson
Malaria is a leading cause of mortality and morbidity globally, and effective vaccines are urgently needed. Malaria vaccine
approaches can be broadly grouped as pre-erythrocytic, blood stage and transmission blocking. This review focuses on blood-
stage vaccines, and considers the evidence supporting the development of blood-stage vaccines, the advantages and challenges
of this approach, potential targets, human vaccine studies and future directions. There is a strong rationale for the development
of vaccines based on antigens of blood-stage parasites. Symptomatic malaria is caused by blood-stage parasitemia and acquired
immunity in humans largely targets blood-stage antigens. Several candidate vaccines have proved efficacious in animal models
and at least one vaccine showed partial efficacy in a clinical trial. At present, all leading candidate blood-stage antigens are
merozoite proteins, located on the merozoite surface or within the apical organelles. Major challenges and priorities include
overcoming antigenic diversity, identification of protective epitopes, understanding the nature and targets of protective immune
responses, and defining antigen combinations that give the greatest efficacy. Additionally, objective criteria and approaches are
needed to prioritize the large number of candidate antigens, and strong candidates need to be tested in clinical trials as quickly
as possible.
Immunology and Cell Biology (2009) 87, 377390; doi:10.1038/icb.2009.27; published online 5 May 2009
Keywords: Plasmodium; malaria; vaccine; blood stage; merozoite
Malaria is an important cause of global mortality and morbidity.
There are an estimated 550 million cases of malaria and 1 million
deaths each year, and around 2.5 billion people are at risk.14 The
malaria field has seen major achievements over the last decade,
including development and implementation of preventive strategies,new treatments and advances in basic research.515 Malaria vaccine
development has been encouraged particularly with trials of the pre-
erythrocytic vaccine, RTS,S, showing protective efficacy.1621 Malaria
vaccines can be considered in three broad groups: pre-erythrocytic,
blood stage and transmission blocking. This review focuses only on
blood-stage vaccines, and considers the evidence supporting the
development of blood-stage vaccines, the advantages and challenges
of this approach, potential targets, human vaccine studies and future
directions.
BACKGROUND
There are five species of Plasmodium that naturally infect humans:P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. These can
cause asymptomatic infection in those with existing immunity, or a
spectrum of clinical disease ranging from mild to severe disease and
death in those lacking substantial immunity. P. falciparum accounts
for the great majority of morbidity and mortality, but P. vivax
also causes considerable symptomatic disease. Estimates suggest that
P. falciparum may be the largest single cause of mortality in children
below 5 years of age.22 Therefore, the efforts to develop vaccines have,
to date, largely focused on P. falciparum.
After an initial period of incubation and replication in the liver, the
blood-stage of the lifecycle commences when merozoites are released
from the infected hepatocytes. The 48 to 72 h-cycle involves mero-
zoites invading erythrocytes, intra-erythrocytic development and
asexual reproduction, erythrocyte rupture and the release of newmerozoites to continue the cycle (Figure 1). Erythrocyte invasion is
thought to occur over several steps involving multiple receptorligand
interactions. Initial attachment of the merozoite to the erythrocyte
surface is followed by apical reorientation, tight-junction formation,
entry into the erythrocyte through an actinmyosin motor, and is
completed by resealing of the erythrocyte membrane.23 This occurs
over 12min and is the only time that the parasite is directly exposed
to the extracellular environment during the blood stage. For most of
the blood-stage cycle, parasites are partially hidden from immune
recognition inside the erythrocyte, which lacks major histocompat-ibility complex molecules. The parasite exports proteins to the
erythrocyte surface, enabling cytoadherence to a range of endothelial
receptors, facilitating sequestration and reducing splenic clearance,
and these seem to be important immune targets.
Clinical illness occurs only during blood-stage infection, with the
liver stage of the infection being asymptomatic. The pathogenesis of
disease is complex and is reviewed elsewhere.24,25 Despite the com-
plexity of the parasite lifecycle, a high level of antigenic diversity and
parasite mechanisms of immune evasion, naturally acquired immu-
nity to malaria does develop after repeated exposure. This immunity
affords protection against symptomatic disease, high-density
Received 6 February 2009; accepted 15 March 2009; published online 5 May 2009
Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Correspondence: Dr JG Beeson, Department of Infection and Immunity, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia.
E-mail: beeson@wehi.edu.au
Immunology and Cell Biology (2009) 87, 377390& 2009 Australasian Society for Immunology Inc. All rights reserved 0818-9641/09 $32.00
www.nature.com/icb
http://dx.doi.org/10.1038/icb.2009.27mailto:beeson@wehi.edu.auhttp://www.nature.com/icbhttp://www.nature.com/icbmailto:beeson@wehi.edu.auhttp://dx.doi.org/10.1038/icb.2009.27 -
8/2/2019 Review on Blood Stage Vaccine Against Malarai
2/14
parasitemia and death; however, it is less effective at preventing low-
level parasitemia.26,27 Naturally acquired immunity seems to predo-
minantly target blood-stage parasites.28
Effective immunity involves both humoral- and cell-mediated
immune responses, which gives some cross-species and cross-strain
protection, though this seems to be limited.29,30 The importance of
antibodies has been supported by the passive transfer of immunoglo-
bulin from immune individuals conferring protective benefit to non-immune individuals.31,32 Immune effector mechanisms are poorly
understood and the relative importance of different mechanisms has
not been quantified. Antibodies may have a role in preventing
merozoite invasion, clearance of infected erythrocytes, prevention of
adhesion and sequestration in the vasculature, and prevention of
schizont rupture. Cytophilic IgG subclasses seem to be particularly
important.3336 They probably facilitate parasite clearance in the
spleen through opsonization for phagocytosis, antibody-dependent
cell-mediated cytotoxicity, and complement-mediated lysis.26,3739
Antibodies do not act alone and there is increasing evidence of the
importance of T cells, not only in providing B cell help, but in
activating Th1 responses, which help mediate antibody effector
mechanisms, as well as cell-mediated effector mechanisms.
ADVANTAGES AND CHALLENGES OF A BLOOD-STAGE VACCINE
It is likely that a highly effective malaria vaccine will need to be
multivalent and may need to incorporate antigens of several lifecycle
stages. There is a strong rationale for developing blood-stage vaccines
as part of this strategy. Pathogenesis of malarial disease results fromblood-stage infection and studies in humans and animal models have
clearly established that immune responses targeting blood-stage anti-
gens can protect against disease or facilitate control of parasite-
mia.31,32,40,41 Immunization with blood-stage antigens, mainly
merozoite antigens, has been shown to be protective in a number of
animal models using different antigens and there was some protective
effect with one blood-stage vaccine tested in humans.4246 At present,
the leading blood-stage vaccine candidates are all merozoite proteins,either located on the merozoite surface or contained within the apical
organelles (Figure 2).
1
2 3 4
1
2 3
4
5
Figure 1 The blood-stage lifecycle of Plasmodium. (a) Merozoites are an
extracellular form of Plasmodium (1) that attach and invade erythrocytes
(2). The parasite then matures and divides through asexual replication inside
the erythrocyte (3). The expression of parasite proteins on the surface of the
infected erythrocyte enables interactions with receptors on the endothelial
surface, facilitating sequestration of parasite-infected erythrocytes in various
organs. After asexual replication, the schizont form ruptures and releases
new merozoites into the circulation (4). (b) Merozoite invasion of
erythrocytes. Merozoites are initially free in the intravascular space after
schizont rupture (1), and the process of erythrocyte invasion commences
when a merozoite binds to the surface of an erythrocyte (2). The merozoite
then reorients its apical end to come into contact with the erythrocyte
surface (3). A series of irreversible high-affinity ligandreceptor interactions
then occur between the parasite and the erythrocyte, enabling tight-junction
formation (4) and entry of the erythrocyte through an actinmyosin motor. As
it does so, the parasite invaginates the erythrocyte membrane to form theparasitophorous vacuole. Outer surface proteins are partially cleaved as the
merozoite enters the erythrocyte (5).
Micronemes
Merozoite surface
Dense granules
Nucleus
Rhoptries
Apicoplast
Mitochondrion
Apical end
MSP1, 2, 4, 5, 10 (GPI anchored)MSP3, 6, 7, 9 (ABRA)GLURPSERAS-antigen6-cys family (GPI anchored)
AMA1
EBA175, 140, 181MTRAPPTRAMPASP
Rh 1, 2a, 2b, 4, 5RAP1, 2, 3RhopH1, 2, 3RAMA
Merozoite surface proteins
Micronemes
Rhoptries
Figure 2 The structure and major antigens of the P. falciparum merozoite. The apical end of the merozoite has specific organelles involved in erythrocyte
invasion, including the paired rhoptries and micronemes, which are thought to expel proteins to bind to erythrocyte receptors during invasion. The merozoite
also has dense granules, and an apicoplast (a plastid remnant). Merozoite ligands and vaccine candidate antigens are present in the organelles and on the
surface of the merozoite. Surface proteins may be GPI anchored or associated with GPI-anchored proteins by molecular interactions. Listed are known
proteins of the merozoite surface and organelles, but many others remain to be identified or characterized.
Blood-stage vaccines against malariaJS Richards and JG Beeson
378
mmunology and Cell Biology
http://www.nature.com/icbhttp://www.nature.com/icb -
8/2/2019 Review on Blood Stage Vaccine Against Malarai
3/14
One hurdle for the continued development of blood-stage vaccines
is the perceived lack of progress despite many years of research. There
are many reasons why development of blood-stage vaccines has not
progressed more rapidly, but slow progress has been common to all
strategies including pre-erythrocytic stage candidates. Clearly greater
effort and funding is needed to facilitate the development and
evaluation of promising vaccines. The Combination B vaccine,
which showed protection against parasitemia, was conducted over10 years ago. However, no further testing of this vaccine or any of its
components in phase II studies has been conducted since. At the time
of writing, only four blood-stage vaccines have been tested in phase II
trials. Of the two that are published, Combination B showed some
degree of efficacy, whereas merozoite surface protein 1 (MSP1)-42 did
not. Although RTS,S, which is based on the circumsporozoite protein,
has been efficacious in several trials, another pre-erythrocytic vaccine,multi-epitope thrombospondin-related adhesion protein (ME-
TRAP)47,48 was not protective. It is likely that few of the vaccines
that are eventually tested in clinical trials will prove to be sufficiently
efficacious; therefore, poor outcomes with specific antigens should not
justify abandonment of an overall strategy.
Recently, there has been a renewed call for the eradication ofmalaria.49,50 An effective vaccine will probably be needed to achieve
eradication, in addition to other existing measures. Part of the
renewed push for eradication of malaria is an emphasis on approaches
to reduce malaria transmission and not just clinical illness. Therefore,
vaccines inducing sterile immunity and/or transmission-reducing
activity would be preferred. The role of blood-stage vaccines as partof this strategy has been questioned, as the objective of blood-stage
vaccines is to reduce parasitemia and prevent clinical illness. However,
data from animal models and clinical studies suggests that controlling
parasite density reduces the generation of gametocytes in the blood
stream. Therefore, it seems likely that an effective blood-stage vaccine
will have benefit in reducing transmission, in addition to preventing
clinical illness.
Perhaps the greatest challenge in developing a blood-stage vaccine isovercoming antigenic diversity. Most, if not all, important antigens
show substantial polymorphism.5154 Antigenic diversity has evolved
to facilitate immune evasion and vaccine approaches need to account
for this such that they will cover the majority of strains causing
infection and disease. This approach may be difficult or impossible if a
large number of different allelic forms of an antigen are required in a
single vaccine. However, the degree of polymorphism is much less for
some antigens than others, and most antigens have domains or
regions that are less polymorphic or are conserved. These may be
suitable targets of vaccines to overcome the problem of antigenicdiversity. Some antigens, such as P. falciparum erythrocyte membrane
protein 1 (PfEMP1), are encoded by large multigene families and
parasites can switch the expression of different genes to facilitate
immune evasion. Recent studies have also shown that some merozoite
protein families can be differentially expressed to facilitate immune
evasion.5557
Further challenges are presented by potential mechanisms of
immune interference seen during natural exposure to Plasmodium
infection. As natural immunity is principally directed against blood-
stage antigens, this may be more important than for pre-erythrocytic
and transmission-blocking vaccines. For example, non-functionalantibodies that impair the binding of functionally important anti-
bodies to merozoite antigens have been identified.58,59 There are also
likely to be effects of earlier exposure or maternally transferred
antibodies in altering immune responses to a vaccine.60,61 Some
data suggests that there may be compromised dendritic cell function
and suppression or deletion of memory B cells, and long-lived plasma
cells during infection.62
VACCINE APPROACHES
Current day immunization evolved from the live-attenuated or whole-
killed vaccines of Jenner, Pasteur and Koch. Even today, the majority
of licensed vaccines use whole organisms. Recent advances have led to
renewed interest in using genetically attenuated parasites as a basis fora malaria vaccine. Most malaria vaccine research, however, has
followed subunit approaches in which antigens are identified, purified,
characterized and then immunologically evaluated.63 This approach
lends itself to using recombinant antigens, peptides and, more
recently, viral vectors.
Whole blood-stage parasites
The whole parasite approach for malaria has partly evolved from
studies of radiation-attenuated sporozoite studies, reviewed else-
where.64 Some information on blood-stage immunity can be gleaned
from early studies in which deliberate infection with Plasmodia was
used to treat paresis in humans. These studies indicated that infection
led to predominantly strain-specific immunity that limited sympto-matic disease, but did not prevent re-infection.65 Other studies in
animal models also suggest that immunity induced in this way is
largely strain-specific.66,67 More recently a study administered live P.
falciparum parasites intravenously at low dose to five patients,
followed by early anti-malarial treatment.68 Four patients were rechal-
lenged with live parasites of the same strain, and three did not developany detectable parasitemia before final anti-malarial treatment. Sur-
prisingly, these patients developed cell-mediated immune responses,
but a limited antibody response.
Whole organism approaches have a range of potential advantages
and these are more thoroughly reviewed elsewhere.6971 In short, they
have the benefit of not requiring the precise determination of epitopes
or antigens. Rather the whole organism enables a vast array of antigens
to be delivered, essentially providing a multi-epitope vaccine, with ahigh probability of antigens being in their native conformation. There
are several important challenges to this approach. Safety is a major
concern, as current technology requires that parasites are cultured in
human erythrocytes, which is accompanied by a risk of serious blood-
borne infections. Large-scale production of whole parasites ensuring
consistent quality and dose is more challenging than for recombinant
or synthetic vaccines. With live-attenuated parasites there is also the
concern that attenuated parasites might revert to a non-attenuated
state, although genetic attenuation by targeting multiple genes would
make this unlikely. There are likely to be significant challenges inproducing and delivering live blood-stage parasites for widespread
use. In vitro culture of P. vivax is difficult to sustain and large-scale
production is not currently feasible.
Recombinant antigens
An advantage of this approach is the ability to direct immune
responses to a specified region or epitope. This has the potential to
maximize protective responses whilst minimizing undesired responses.
A further advantage is the suitability for large-scale antigen produc-
tion under good manufacturing practice. The inherent difficulty is
identifying protective target antigens for development, or specificdomains of proteins, and the likelihood that multiple antigens
would be required to induce an effective response and overcome
antigenic diversity. Expression of many Plasmodium proteins is
problematic because they are often conformationally complex and/
or large. Most recombinant antigens require some form of adjuvant to
Blood-stage vaccines against malariaJS Richards and JG Beeson
379
Immunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
4/14
elicit sufficient immune responses. There is much uncertainty about
which proteinadjuvant combinations will be well-tolerated, yet elicit
an effective immune response with sustained duration.
Peptide vaccines
Peptide vaccines have the potential to deliver precisely defined
epitopes with a large scale of production at relatively low cost. 72,73
Using a totally synthetic approach is perhaps the safest manufacturingmethod, and largely avoids concerns of microbiological contamina-
tion. There is also the potential to synthesize or conjugate multiple
epitopes into a single construct. However, there are major challenges to
synthesizing conformational epitopes; peptide antigens with limited
epitopes may not elicit adequate immune responses in children and in
certain human leukocyte antigen (HLA) subgroups.74 There are
approaches to overcome some of these barriers in which peptidescan be conjugated to T-cell epitopes, lipid moieties, or suspended in
liposomes or virus-like particles.75 Similarly, peptides are more amen-
able to engineering to potentially improve immunogenicity and can be
built into scaffolds to mimic native conformation.72,76 At present, a lack
of knowledge regarding functionally relevant or protective epitopes of
major antigens is a major impediment for the development of peptide-based vaccines, and clearly represents an area for further studies.
DNA and viral-vectored vaccines
The application of DNA and viral-vectored approaches for malaria
vaccines is beginning to emerge and is reviewed elsewhere.7781 Most
employ prime-boost strategies, but use different viral vectors and arange of different formulations, including liposomes, virosomes,
microspheres and nanoparticles.82 They offer the advantage of includ-
ing multiple antigens and have been shown to effectively induce both
cell-mediated immunity and specific antibodies.
POTENTIAL TARGETS AND THEIR PRIORITIZATION
Prioritizing antigens
Until recently, research efforts have focused on a handful of individualantigens. Perhaps the greatest advance for malarial research in the past
decade has come from completion of major genome projects, includ-
ing P. falciparum, P. vivax, P. knowlesi, P. berghei, P. chabaudi and P.
yoelii.15,8388 Thousands of novel proteins have been identified,5,89
providing new opportunities for vaccine development. However, at
present, little is known about their structure and function or their role
as targets of protective immunity.
Several criteria can be used to objectively prioritize known and
predicted antigens for further study.15,85 Table 1 lists some important
properties that could be used in this process, and rates five vaccinecandidates against these criteria as an example. Targeting proteins that
have an important function seems obvious, but the function is known
for very few antigens. In some instances structural features may be
suggestive of function (for example, epidermal growth factor domains
in MSP1-19), and others have been classified as essential or non-
essential on the basis of whether they can be genetically disrupted or
not.90 Surface exposure or location within the apical organelles of the
merozoite is likely to be highly relevant, but defining surface-exposed
epitopes within antigens has proven to be more challenging. An
increasing amount of data is emerging about polymorphisms, which
may indicate targets under the pressure of immune selection, and
regions or proteins of limited diversity. Abundance of proteins varies
widely (for example, MSP1 vs MSP4), which may have implicationsfor the extent and nature of immune responses. Structural features
and the size of antigens have implications for vaccine manufacture.
Studies of naturally acquired immunity can facilitate the identification
of antigen-specific immune responses involved in protective immunity
and the identification and characterization of immune effector
mechanisms. At present, there is an over reliance on using standardimmunoassays of uncertain functional significance, and the develop-
ment and application of functional assays is greatly needed.
Potential targets and results from vaccine trials
Human trials of blood-stage malaria vaccines have only been carried
out with whole blood-stage parasites and merozoite antigens to date.
Table 2 summarizes clinical trials that have been conducted or are in
progress. Here, we discuss findings from these trials and the propertiesof vaccine antigens. Unfortunately, it was beyond the scope of this
review to comprehensively include vaccine testing in animal models.
Table 1 Pre-clinical criteria for prioritizing candidate antigens for vaccine development
Criteria
Current vaccine candidatesa
MSP1-42 MSP2 MSP3 LSP AMA1 EBA175 RII
Known functionb No No No No Yes
Essential or important functionc Yes Yes No/unknown Yes Yes
Location Merozoite surface Merozoite surface Merozoite surface Apical Apical
Abundance of antigen High High High Low Low
Limited diversityd No No Yes No Yes
Possible target of protective immunity in humanse Yes Yes Yes Yes Yes
Antibodies inhibit parasite growth in vitrof Yes Unknown Yesg Yes Yes
Vaccination induces protective immunity in non-human primate models h Yes Unknown Yes Yes Yes
Phase II vaccination in humansi Not protective Protective Trial ong oing Trial ong oing No t tested
Abbreviations: AMA, apical membrane antigen; EBA, erythrocyte-binding antigens; LSP, long synthetic peptide; MSP, merozoite surface protein.aFive leading vaccine antigens were selected as illustrative examples.bEBA175 binds to glycophorin A on the erythrocyte surface.cEssential function defined as an inability to knock out the gene in transfection studies. MSP3 is not essential, and its function is unknown.dMSP3 is polymorphic, but the LSP construct is highly conserved.eStudies of endemic populations have found naturally acquired antibodies associated with protection from symptomatic disease (this does not mean that antibodies are causally responsible forprotection).fStandard assay is the growth inhibition assay without immune cells.gMSP3 antibodies do not have direct growth inhibitory activity but show antibody-dependent cellular inhibition.hMSP2 has not been tested in non-human primates. It is not possible to test it in murine models.iPhase II vaccination in humans is meant to serve as a comparison of how the criteria predict the final outcomes.
Blood-stage vaccines against malariaJS Richards and JG Beeson
380
mmunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
5/14
Table 2 Summary of vaccine studies in humansa
Stage Antigen Vaccine Trial
phase
Site Participants Status References
Erythrocytic Whole parasite Low-dose live parasites/drug cureb I/II Australia five adults Completed 68
MSP1-42 FMP1/ASO2 I USA 15 adults Completed 108
FMP1/ASO2 I Kenya 40 adults Completed 109
FMP1/ASO2 I Mali 40 Completed 110
FMP1/ASO2 I Kenya 135 children
14 years
Completed 242
FMP1/ASO2c II Kenya 400 children
14 years
Completed NP
MSP1-42 (3D7 or FVO)/alum I USA 60 adults Completed 112,243
MSP1-42-C1/alhydrogel (+/CPG 7909) I USA 60 adults Completed NP
MSP1 FMP010/ASO1 I USA 25 adults Completed NP
MSP2 MSP2 (3D7+FC27) I Australia 45 adults Completed NP
MSP3 MSP3 LSP/alum/ISA720 I Switzerland 35 adults Completed 131,132
MSP3 LSP/alum I Burkina Faso 30 adults Completed 135
MSP3 LSP/alum I Tanzania 45 children
12 years
Recruiting NP
MSP3 LSP/alum I Burkina Faso 45 children
12 years
Recruiting NP
MSP3 LSP/alumc II Mali 378 children
12 years
Recruiting NP
AMA1 AMA1-C1/alhydrogel I USA 30 adults Completed 147
AMA1-C1/alhydrogel I Mali 54 adults Completed 148
AMA1-C1/alhydrogel I Mali 36 children
23 years
Completed 149
AMA1-C1/alhydrogelc II Mali 900 children
23 years
Completed NP
AMA1-C1/alhydrogel (short schedule) I USA 18 adults Completed NP
C1/alhydrogel +/CPG 7909 I USA 75 adults Completed 150
C1/alhydrogel +/CPG 7909 I Mali 24 adults Completed NP
C1/alhydrogel +/CPG 7909 I Mali 200 children
13 years
Recruiting NP
C1/alhydrogel +CPG 7909b I/II UK 21 adults Not started NP
C1/alhydrogel +/CPG 7909 (high/low) I USA No. not stated-adults Completed NP
C1/alhydrogel +/CPG 7909 (saline/phosphate) I USA 24 adults Completed NP
C1/alhydrogel/ISA720 I USA 28 adults Completed NP
FMP2.1/ASO2 I USA 23 adults Completed 151
FMP2.1/ASO2 I Mali 60 adults Completed NP
FMP2.1/ASO2 I Mali 100 children
16 years
Completed NP
FMP2.1/ASO2c II Mali 400 children
16 years
Active NP
FMP2.1/ASO2/ASO1 I USA 35 adults Completed NP
PfAMA1-FVO/alhydrogel/ISA720/ASO2 I Netherlands 56 adults Completed 155
PfAMA1-FVO/alhydrogel/ISA720/ASO2 I Mali 60 adults Recruiting NP
EBA175 EBA175 RII-NG I USA 80 adults Completed NP
GLURP GLURP LSP I Netherlands 36 adults Completed 187
SERA5 SE36 I Japan Not specified Completed 244
Blood-stage vaccines against malariaJS Richards and JG Beeson
381
Immunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
6/14
Merozoite surface antigens. Merozoite surface protein 1 coats
the merozoite surface and is GPI (glycosylphosphatidylinositol)
anchored.91,92 It undergoes several proteolytic processing steps creat-
ing several fragments, of which the 42 kDa (MSP1-42) and 19 kDafragment (MSP1-19) have been most studied.93 The crystal structure
for MSP1-19 has been elucidated.94,95 Its function seems to be
essential, probably for initial attachment of merozoites to the ery-
throcyte surface through a complex with MSP9.96,97 There are two
major allelic variants, MAD20 and K1, with highly polymorphic (for
example, Block 2) and relatively conserved regions (for example,
MSP1-19).98 Antibodies to MSP1-19 have been variably associated
with protection from symptomatic disease.99103 Vaccine-induced
antibodies have invasion inhibitory activity and may also inhibit
MSP1 processing.103,104 Vaccination of mice and primates protected
from subsequent challenge in some studies.43,105107 Human vaccinestudies include MSP1-42 (3D7) formulated with adjuvant, ASO2A,
(GlaxoSmithKline, Brentford, Middlesex, UK) that induced growth
inhibitory antibodies.108110 However, a Phase II trial among 12 to 47-
month-old children in Kenya found no protective effect.111 Phase I
studies of MSP1-42 (3D7 and FVO) in Alhydrogel (Sigma-Aldrich,
St Louis, MO, USA) generated moderate antibody responses, but
insufficient in vitro inhibitory activity.112 MSP1-19 has only been
tested in human vaccine studies as part of the chimeric vaccine,
PfCP2.9, which combines domain 3 of apical membrane antigen 1(AMA1) (3D7).113,114 In phase I studies, adjuvanted with Montanide
ISA720, (SEPPIC SA, Paris, France) there was high immunogenicity,
but significant reactogenicity.115,116 Antibody invasion inhibitory activ-
ity was weak, as were T-cell responses. Human trials with P. vivax
antigens have not yet been carried out. However, immunization using
PvMSP1-19 had some protective effect in a non-human primate
challenge.117
Merozoite surface protein 2 (MSP2) is also GPI anchored to the
merozoite surface. Its function remains unclear, but also seems to be
essential.90 There are two major allelic families (FC27 and 3D7) each
with a highly variable central region consisting of several repeats andconserved flanking regions.54 Natural immunity results in high levels
of antibodies, predominantly IgG3 and a moderate association with
protection from symptomatic disease.36,118 MSP2 (3D7) was included
in the Combination A vaccine, adsorbed onto Alum and found to be
safe, but poorly immunogenic.119 Five patients were challenged by
Table 2 Continued
Stage Antigen Vaccine Trial
phase
Site Participants Status References
MSP1/MSP2/RESA Combination B/ISA720 I Australia 32 adults Completed 120
Combination B/ISA720 I Australia 36 adults Completed 120
Combination B/ISA720b I/II Australia 17 adults Completed 121
Combination B/ISA720 I Papua New Guinea 12 adults Completed 122
Combination B/ISA720c I/II Papua New Guinea 120 children
59 years
Completed 42,123125
AMA1/MSP1-19 PfCP2.9/ISA720 I China 52 adults Completed 115
PfCP2.9/ISA720 I China 70 adults Completed 116
MSP3/GLURP GMZ2/alum I Germany 30 adults Recruiting NP
GMZ2/alum I Gabon 40 adults Recruiting NP
GMZ2/alum I Gabon 30 children
15 years
Recruiting NP
SPf66d
Multistage Polyprotein
(six antigens)
FP9-PP, MVA-PP I UK 35 adults Completed NP
FP9-PP, MVA-PPe II UK 26 adults Completed NP
AMA1/CSP PEV301 (AMA1), PEV302 (CSP),
PEV3A (PEV301+PEV302)
I Switzerland 46 adults Completed 159
PEV3A (AMA1+CSP), FP9 ME-TRAPe I/II UK 30 adults Completed 158
A MA1/CS P A MA1/CS P/Adeno5f I/II USA 70 adults Recruiting NP
NYVAC-Pf7 CSP, SSP2, LSA1, MSP1, AMA1, SERA, Pfs25e I/II USA 59 adults Completed 220
MSP2/ CSP Combi nation A/alume I/II Switzerland 39 adults Completed 119
Abbreviations: AMA, apical membrane antigen; EBA, erythrocyte-binding antigens; GLURP, glutamate-rich protein; LSP, long synthetic peptide; MSP, merozoite surface protein; NP, Not published;
SERA, serine repeat antigen; SSP, sporozoite surface protein; TRAP, thrombospondin-related adhesion protein.aSome of this information is gathered from www.clinicaltrials.gov and is the most accurate publically available data at the time of writing.bBlood stage challenge.cNatural exposure.dSPf66 underwent numerous clinical studies which are comprehensively reviewed elsewhere.eSporozoite challenge.
Blood-stage vaccines against malariaJS Richards and JG Beeson
382
mmunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
7/14
mosquito bite, but no protective benefit was detected. Combination
B comprised of MSP1 (190LCS.T3, N terminal end, K1 allele), MSP2
(3D7) and a part of the ring-infected erythrocyte surface antigen
(RESA) in Montanide ISA720. Phase I/II studies among children in
Papua New Guinea reported lower parasite densities in the vaccine
recipients.42,120123 Furthermore, the risk of infection with the MSP2
allelic variant included in the vaccine (3D7) was much lower than the
risk with the alternate allelic variant (FC27), suggesting that theantigen mediating the major protective effect was MSP2.124,125
Merozoite surface protein 3 (MSP3) has neither a GPI anchor nor
typical transmembrane domain, but is non-covalently attached to the
merozoite surface. Its function is unknown, but it seems to interact
with acidic basic repeat antigen (ABRA, also known as MSP9) and can
be genetically disrupted.126 It has allelic dimorphism (K1 and 3D7)
with the C-terminal end being conserved and the N terminal endbeing highly polymorphic.127129 Antibodies have been associated with
protective immunity in studies of acquired immunity in humans.130
MSP3 vaccines based on the conserved C-terminal end of the protein
expressed as a long synthetic peptide have been tested in clinical
trials.131,132 The vaccine was immunogenic, mostly of IgG3 subclass,
but antibody titers were not sustained. Antibodies have not beenshown to directly inhibit invasion, but instead seem to act in
cooperation with monocytes to inhibit parasite replication in
vitro.131,133,134 A phase I study in Burkina Faso failed to show any
vaccine-related boosting of MSP3 antibody responses above the high
level seen at enrollment.135 There are two phase I studies and a phase
II study examining this vaccine in children from endemic countries.There are also three phase I studies currently recruiting using a MSP3/
GLURP (glutamate-rich protein) chimera.136
Proteins of the apical organelles of merozoites. The apical organelles of
the merozoite contain a number of known or predicted invasionligands. One of these, AMA1 is thought to play an essential role in
erythrocyte invasion, however, its precise function is not known.137 Its
crystal structure has recently been solved and it is thought to form acomplex with rhoptry neck protein 4 (RON4).138,139 AMA1 is highly
polymorphic and allele-specific antibodies are not cross-protective;
presenting a major challenge to vaccine development.52,140143
Acquired antibodies have been associated with protection from
symptomatic disease in humans.36,144 Antibodies have been shown
to inhibit invasion in functional assays, although non-functional
antibodies are also prevalent.141,145 Immunization with AMA1 was
protective in primate studies.146
There have been numerous AMA1 human vaccine studies, mainly
phase I studies to date. The AMA-C1 (3D7 and FVO strains) vaccine,adjuvanted with Alhydrogel, was safe and immunogenic, and gener-
ated antibodies that inhibited parasite growth in vitro.141,147 This was
confirmed in Malian adults and children, but antibody levels were not
maintained.148,149 A phase II study is presently underway. There are a
range of studies examining other adjuvants. Adding CPG 7909 to the
Alhydrogel formulation led to three- to fourfold higher antibody
titers.150 There was significant invasion inhibition, but this was
relatively variant-specific. In phase I trials, the FMP2.1 vaccine (3D7
strain) adjuvanted with ASO2A generated high-titre antibodies that
inhibited growth and AMA1 processing.144,151,152 It also resulted in
cell-mediated immune responses. Phase II studies are currently under-way. ASO1B is also being explored as an alternative adjuvant (unpub-
lished). The PfAMA1-FVO construct has been formulated with a
range of adjuvants, including Alhydrogel, Montanide ISO720 and
ASO2.153155 Antibody titers were highest with ASO2, and were
maintained for longer and inhibited in vitro invasion. This vaccine
is being studied in Malian adults. The NMRC-M3V-Ad-PfCA vaccine
contains CSP (circumsporozoite protein) and AMA1 (3D7) using an
adenovirus 5 vector. The PEV301, PEV302, PEV3A (AMA1/CSP
peptide) vaccines use influenza virosomes to deliver an AMA1-
containing peptide from loop I of domain III (K1 strain), as well as
a double loop of NPNA repeats of the CSP peptide. 156,157 Phase I and
II studies showed good safety and immunogenicity with high antibody
levels, high avidity and recognition of blood-stage parasites.158,159
Sporozoite challenge failed to afford sterile protection or to prolong
time to parasitemia, but vaccine recipients had lower parasite growth
rates and had morphologically altered parasites detected.
The erythrocyte-binding antigens (EBAs) are a family of antigens,
which are orthologues of the Duffy-binding protein of P. vivax and
include EBA175, EBA140 (BAEBL), EBA181 (JESEBL), MAEBL, EBL1
and EBA165 (pseudogene). On each of these proteins, there is areceptor-binding domain (region II), which is structurally related
between proteins, but differs in sequence; the crystal structure was
recently solved for EBA175.160 They are located in the micronemes
and are secreted onto the merozoite surface just before invasion.161163
It is known that EBA175 and EBA140 interact with glycophorin A and
C, respectively.164167
Vaccine-induced antibodies in animals inhibitinvasion.165,168,169 There is limited sequence polymorphism in the
receptor-binding domains, but this does not seem to affect the activity
of vaccine-induced antibodies.170 Overall, there is little polymorphism
throughout the protein. Acquired antibodies among children have
been associated with protection from symptomatic disease in some
studies.171,172 Parasites can vary the expression and use of these ligandsduring invasion, which seems to facilitate immune evasion, and the
EBAs seem to function in a complementary manner with the
reticulocyte binding-like homologs (PfRHs).56 The only human vac-
cine study is a phase I study of EBA175 region 2 adsorbed onto
aluminum phosphate (unpublished). An EBA175 vaccine was shown
to have efficacy in a primate challenge.173
Very little work has been carried out on the development of P vivax
vaccines. However, the Duffy-binding protein (DBP) is a strongvaccine candidate. DBP binds to DARC (Duffy antigen/receptor for
chemokines) during parasite invasion of reticulocytes.174,175 DBP
seems essential for invasion, and resistance to P. vivax in humans
is conferred by a lack of DARC expression.176,177 DBP is localized in
the micronemes,174 and is thought to be essential for the formation of
the tight junction. The receptor-binding face of the protein has
little polymorphism suggesting that it may be possible to develop a
vaccine that predominantly targets the conserved region to block the
DBPDARC interaction. Studies have shown that vaccine-induced
antibodies in animals and acquired human antibodies can inhibitreticulocyte invasion and inhibit the binding of DBP to DARC.178,179
Furthermore, DBP-binding inhibitory antibodies have been
associated with acquired protective immunity in humans and immu-
nization with DBP was partially protective in a primate challenge
model.180,181
Other merozoite antigens. Glutamate-rich protein is expressed on the
merozoite surface and in liver stage schizonts,182 but its function is
unknown. It has two repeat regions (R1 and R2), and an N-terminal
non-repeat region which has limited diversity (R0).183 Naturally
acquired antibodies of IgG1 and IgG3 subclasses (depending on theantigenic region) are variably associated with protection.184186
Human vaccine studies have focused on a long synthetic peptide
derived from the R0 region. A phase I study with glutamate-rich
protein long synthetic peptide adjuvanted in alum or Montanide
ISA720 generated antibodies that inhibited parasite growth in coop-
Blood-stage vaccines against malariaJS Richards and JG Beeson
383
Immunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
8/14
eration with monocytes.187 It has also been examined in combination
with MSP3.
Future malaria vaccine research will need to assess the potential of
other antigens, which have been identified, but have not yet been
tested in humans. The reticulocyte binding-like homologs (PfRHs) are
a family of invasion ligands that have homology with the reticulocyte-
binding proteins of P. vivax. They are found in the neck of the
rhoptries and are known to bind to erythrocytes, but receptors remainto be identified. Antibodies are acquired naturally and have been
strongly associated with protection.188 Antibodies to PfRH1 and
PfRH2 have been shown to inhibit invasion, and polymorphism in
the PfRH proteins is limited. MSP4 is GPI anchored to the merozoite
surface, has limited diversity and elicits naturally acquired antibodies,
though these are not associated with protection.189191 Vaccination
with the P. yoelii homologue, MSP4/5, is protective in murinechallenge.192,193 There many other promising candidates, amongst
these are the SERA (serine repeat antigen) family, RhopH1-3, and the
6-cysteine domain family.
Variant surface antigens. Antibodies against variant surface antigens
(VSAs) expressed on the surface of the infected erythrocyte arethought to contribute to strain-specific protection in humans and
primate models.66,194 Studies in monkeys also suggest that VSAs are
important targets of protective antibodies. VSAs include PfEMP1,
rifins, subtelomeric variable open reading frame (STEVOR), and
others;25 to date, only PfEMP1 has been established as a major target
of antibodies.195,196 PfEMP1 is encoded by the var multigene family,
and different var genes encode PfEMP1 variants with different anti-
genic properties.197 The immune response against VSAs is thought to
contribute to strain-specific protection, but only PfEMP1 has been
established as a major target of antibodies.194 There is a high level of
polymorphism between different var genes within a single genome
and between vargenes in different genomes. Rifins and STEVOR are
also encoded by large polymorphic gene families. The major barrier to
developing VSAs as vaccines is their very high degree of antigenic
diversity and capacity for clonal antigenic variation. Studies are
beginning to identify subsets of var genes associated with severe
disease that are likely to be important immune targets.198200 Some
studies have suggested that cross-reactive antibodies can be generateddespite extensive polymorphism and a vaccine trial in primates
showed protection against homologous parasites.201,202 A specific
variant of PfEMP1 (var2csa) is expressed by P. falciparum-infected
erythrocytes that mediates adhesion to the placental lining during
pregnancy and seems to be an important target of acquired anti-
bodies.203 Var2csa is less antigenically diverse than other PfEMP1
variants and antibodies that cross-react with different placental-bind-
ing isolates have been shown in humans and animal models. There-
fore, it may be possible to develop a vaccine inducing broad coverageagainst different placental-binding variants by targeting conserved
and/or common epitopes of var2csa.204206
Other antigens. Glycosylphosphatidylinositol is a glycolipid that
anchors a number of erythrocytic stage proteins to the membrane,
including MSP1, MSP2 and serine proteases. It has been reported to
have toxin-like effects and induce pro-inflammatory responses and
clinical symptoms in murine models (reviewed in Schofield andGrau207). Immunization with a synthetic version of the GPI glycan
showed some protection against clinical illness in mice, providing a
proof-of-concept for this type of approach.208 The vaccine did not
have any affect on parasite replication and it is likely that GPI would need
to be included in a multivalent vaccine rather than being used alone.
Other human vaccine studies. The SPf66 vaccine consists of a 45
amino-acid peptide, which is a chimera of three merozoite-derived
epitopes interspersed with the PNANP sporozoite peptide of CSP.
Most studies have examined it adjuvanted with aluminum hydroxide.
It showed mild protective efficacy in a South American and a
Tanzanian study, but failed to show any benefit in the studies
conducted in Gambia or Thailand.209217 Much controversy sur-
rounded these studies and it was the subject of a Cochrane review,which concluded that there was no justification for further trials using
the same formulation.218
The NYVAC-Pf7 vaccine incorporates seven genes into an attenu-
ated vaccinia virus. These genes included blood-stage antigens, MSP1,
AMA1, SERA as well CSP, liver-stage antigens 1 (LSA1), sporozoite
surface protein 2(SSP2) and the 25 kDa sexual-stage antigen, SPf25.219
In a human sporozoite challenge model, antibody levels in vaccinated
individuals were found to have a slight delay in the prepatent
period.220 The FP9-PP, MVA-PP vaccine is principally a pre-erythro-
cytic vaccine, using the fowlpox 9 (FP9) and the modified vaccinia
virus Ankara (MVA) polypeptide (PP) vaccines, which contain
proteins that are also expressed during the erythrocytic stage.221
RECENT ADVANCES AND CONTINUING CHALLENGES
Determining structure and function
A more complete understanding of the structure and function of
Plasmodium proteins, particularly those involved in host-cell adhesion
and invasion will greatly facilitate the identification, rationalization
and evaluation of candidate antigens. As expected, there will be a lagbetween advances in genomics to that of proteomics, and particularly
functional molecular biology. Remarkably little is known about the
molecular interactions that occur during merozoite invasion, with the
binding partners of most merozoite antigens yet to be identified.222224
This lack of knowledge limits more targeted approaches against
functionally important domains, the significance of sequence poly-
morphism in antigens and the development of functional immuno-
logical assays for vaccine trials. Structural modeling is beginning toinform molecular interactions, including antibodies.95,138,160,225230
This has the potential to assist in epitope mapping and determining
the mechanisms of immune evasion.231,232
Identifying correlates of immunity and developing
functional assays
The identification of robust correlates of immunity and assays that
measure functionally relevant immune responses would be of
enormous benefit for the development of blood-stage vaccines.
Unfortunately there is still much to be done to achieve this goal.Studies of acquired human immunity have largely focused on only a
small number of antigens using standard immunoassays that provide
little indication of the functional relevance of the responses. Very little
is known about functional effector mechanisms and there are few
assays examining these issues.38,39,131,233 Future studies will need to
accommodate the testing of responses to a large number of candidate
antigens that are now being identified, and greater effort is required to
define immune effector mechanisms and their contribution to immu-
nity in humans. For example, the predominant assays for merozoite
vaccines measure direct antibody growth inhibition or antibody-
dependent cellular inhibition.38,39 These assays have been carriedout for many years, but have rarely been applied to large population
studies. The further refinement and optimization of these assays and
the development of high-throughout methods, such as using flow
cytometry, and transgenic parasites to identify and quantify antigen-
specific responses will advance our ability to understand and
Blood-stage vaccines against malariaJS Richards and JG Beeson
384
mmunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
9/14
measure immune responses in studies of acquired and vaccine-
induced immunity.56,59,103,180,234240
Pathway to vaccine development: animal models
and human challenge
In many instances, malaria vaccine research has taken candidate
antigens into rodent studies to determine immunogenicity and
evaluate efficacy using challenge models. Although this approachhas the benefits of being readily available and relatively affordable,
there are considerable limitations. Human malarias cannot infect mice
and rodent malarias lack many important antigens of P. falciparum
and P. vivax, which means that murine challenge models cannot be
used to assess their efficacy. Additionally, there are important differ-
ences between mice and humans in the nature of immune and
pathogenic responses to malaria. More recently, there have been effortsto humanize the mouse model to make it more representative of
human immune responses.131,241 These models may provide an
informative approach to evaluate blood-stage vaccines, but further
studies are needed to establish their relevance. Vaccine testing often
proceeds to challenge studies in non-human primates. This is
expensive, has limited availability, and for P. falciparum, is largelyrestricted to Aotus and Saimiri models. Given the limitations of animal
models for testing malaria vaccines, the safety and immunogenicity of
candidate vaccines in humans should be determined as rapidly as
possible. It could be argued that vaccine candidates that have a very
strong rationale for development, based on a set of widely accepted
biological and immunological criteria, could proceed through tohuman trials without the need for evaluation in animal models.
With the need to progress candidate vaccines more quickly into
human trials, there is an increasing interest in testing vaccines in
humans using a live parasite challenge; this has been carried out either
by direct inoculation of blood-stage parasites or with sporozoites
through mosquito bite. There are a number of significant concerns
about the relevance of this model for evaluating the efficacy of blood-
stage vaccines, and it remains to be established that it is a validapproach. A principle problem with this approach is that participants
must be treated as soon as blood-stage parasitemia is detected for
ethical reasons. Blood-stage immunity acts primarily by limiting
parasite density and protecting against symptomatic illness rather
than preventing parasitization per se. However, it is not possible to
assess clinical illness or high-density parasitemia as an outcome using
this approach, and there is only a limited ability to measure parasite
replication rates before treatment. On-going studies might shed light
on these issues and clarify whether non-human primate challenge orthe human challenge model is more informative for evaluating blood-
stage vaccines. Of interest, the Combination B vaccine did not show
any effect on blood-stage replication in a challenge carried out in
vaccinated malaria-nave individuals, but did show protective effect in
a phase II trial in children in Papua New Guinea. 42,121
CONCLUSIONS AND PERSPECTIVES
In this review, we have highlighted a number of issues surrounding the
development of vaccines against malaria based on antigens expressed
in the blood-stage, as well as summarized recent progress and the
current state of the field. Effective blood-stage vaccines will almost
certainly need to be comprised of several different antigens, or severaldifferent alleles of a single antigen, to overcome antigenic diversity and
the capacity ofP. falciparum for immune evasion or perhaps to achieve
more potent anti-parasite activity by combining antigens that induce
antibodies with synergistic activities against parasite growth. There are
presently a substantial number of blood-stage vaccine candidates and
a multitude of new antigens are likely to emerge from recent genomic
and proteomic insights. Therefore, there is a strong need for
approaches to validate and prioritize potential vaccine candidates
for further development.
The recent success of the RTS, S vaccine in several phase II trials
conducted in African children has changed the landscape of malaria
vaccine development. RTS,S is now entering phase III studies and it
seems likely that it will eventually become licensed for broad use.RTS,S represents a first generation vaccine against malaria, and the
challenge ahead will be to develop the next generation of vaccines that
have greater efficacy and provide more sustained protection. This may
be achieved by combining the RTS,S antigen with other antigens, or
the development of vaccines targeting different antigens altogether.
There is a strong rationale for the continued development and testing
of blood-stage vaccines highlighted in this review, and for investigatingthe inclusion of blood-stage antigens in combination with pre-
erythrocytic antigens, such as the RTS,S antigen. The importance of
blood-stage antigens as targets of acquired immunity in humans
together with the demonstrated efficacy of different blood-stage
antigens in animal models and the partial efficacy of at least one
blood-stage vaccine in humans provides reasonable cause to beoptimistic about the development of blood-stage vaccines against
malaria.
ACKNOWLEDGEMENTSJGB is supported by a Clinical Career Development Award, and JSR by a
Medical Postgraduate Research Scholarship from the National Health and
Medical Research Council of Australia. Thanks to Creepy Crawley Cartoons for
preparing the figures.
1 Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical
episodes of Plasmodium falciparum malaria. Nature 2005; 434: 214217.
2 Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI et al. The limits andintensity of Plasmodium falciparum transmission: implications for malaria control and
elimination worldwide. PLoS Med 2008; 5: e38.
3 Hay SI, Snow RW. The Malaria Atlas Project: developing global maps of malaria risk.
PLoS Med 2006; 3: e473.
4 World Health Organization. World Health Report: Make Every Mother and Child Count.
WHO: Geneva, 2005; cited 15/3/06. Available from: http://www.who.int/whr/2005/en/
index.html.
5 Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW et al. Genome
sequence of the human malaria parasite Plasmodium falciparum. Nature 2002;
419: 498511.
6 Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, Caler E et al. Comparative
genomics of the neglected human malaria parasite Plasmodium vivax. Nature 2008;
455: 757763.
7 Carlton JM, Angiuoli SV, Suh BB, Kooij TW, Pertea M,Silva JC etal. Genome sequence
and comparative analysis of the model rodent malaria parasite Plasmodium yoelii
yoelii. Nature 2002; 419: 512519.
8 Pain A, Bohme U, Berry AE, Mungall K, Finn RD, Jackson AP et al. The genome of the
simian and human malaria parasite Plasmodium knowlesi. Nature 2008; 455:799803.
9 Holt RA, Subramanian GM, Halpern A, Sutton GG, Charlab R, Nusskern DR et al. The
genome sequence of the malaria mosquito Anopheles gambiae. Science 2002; 298:
129149.
10 Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al. Initial
sequencing and analysis of the human genome. Nature 2001; 409: 860921.
11 Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG et al. The sequence of
the human genome. Science 2001; 291: 13041351.
12 Noor AM, Mutheu JJ, Tatem AJ, Hay SI, Snow RW. Insecticide-treated net coverage in
Africa: mapping progress in 20002007. Lancet 2009; 373: 5867.
13 Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS et al. A trial of
combination antimalarial therapies in children from Papua New Guinea. N Engl J Med
2008; 359: 25452557.
14 Malarias watershed. Nature 2008; 455: 707.
15 Hall N, Karras M, Raine JD, Carlton JM, Kooij TW, Berriman M et al. A comprehensive
survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic
analyses. Science 2005; 307: 8286.
Blood-stage vaccines against malariaJS Richards and JG Beeson
385
Immunology and Cell Biology
http://www.who.int/whr/2005/en/index.htmlhttp://www.who.int/whr/2005/en/index.htmlhttp://www.who.int/whr/2005/en/index.htmlhttp://www.who.int/whr/2005/en/index.html -
8/2/2019 Review on Blood Stage Vaccine Against Malarai
10/14
16 Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P et al. Duration of
protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falci-
parum disease in Mozambican children: single-blind extended follow-up of a rando-
mised controlled trial. Lancet 2005; 366: 20122018.
17 Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J et al. Efficacy of the
RTS,S/AS02A vaccine against Plasmodium falciparuminfection and disease in young
African children: randomised controlled trial. Lancet 2004; 364: 14111420.
18 Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J et al. Efficacy of RTS,S/
AS01E vaccine against malaria in children 517 months of age. N Engl J Med 2008;
359: 25212532.19 Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C et al. Safety and
immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008;
359: 25332544.
20 Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE et al. Efficacy
of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in
semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:
19271934.
21 Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S et al.
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian
children. Vaccine 2005; 23: 41484157.
22 Elliott SR, Beeson JG. Estimating the burden of global mortality in children agedo5
years by pathogen-specific causes. Clin Infect Dis 2008; 46: 17941795.
23 Gilson PR, Crabb BS. Morphology and kinetics of the three distinct phases of red
blood cell invasion by Plasmodium falciparum merozoites. Int J Parasitol 2009; 39:
9196.
24 Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature
2002; 415: 673679.
25 Beeson JG, Brown GV. Pathogenesis of Plasmodium falciparum malaria: the roles of
parasite adhesion and antigenic variation. Cell Mol Life Sci 2002; 59: 258271.26 Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol
2006; 28: 5160.
27 Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, Susapu M et al. The risk of
malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg
2007; 76: 9971008.
28 Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev
2009; 22: 1336.
29 Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cellular
immune responses against malaria. Trends Parasitol 2008; 24: 578584.
30 Douradinha B, Mota MM, Luty AJ, Sauerwein RW. Cross-species immunity in malaria
vaccine development: two, three, or even four for the price of one? Infect Immun
2008; 76: 873878.
31 Cohen S, McGregor I, Carrington S. Gamma-globulin and acquiredimmunity tohuman
malaria. Nature 1961; 192: 733737.
32 McGregor IA. The passive transfer of human malarial immunity. Am J Trop Med Hyg
1964; 13 (Suppl): 237239.
33 Tongren JE, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, Nkya WM et al.
Target antigen, age, and duration of antigen exposure independently regulate immu-noglobulin G subclass switching in malaria. Infect Immun 2006; 74: 257264.
34 Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response
to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and
predominantly of the immunoglobulin G3 subclass. Infect Immun 1995; 63:
43824388.
35 Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB et al. Humoral
responses to Plasmodium falciparum blood-stage antigens and association with
incidence of clinical malaria in children living in an area of seasonal malaria
transmission in Burkina Faso, West Africa. Infect Immun 2008; 76: 759766.
36 Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S et al. IgG
subclass-specific responses against Plasmodium falciparum merozoite antigens are
associated with control of parasitemia and protection from symptomatic illness. Infect
Immun2009; 77: 11651174.
37 Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long CA et al.
Critical evaluation of different methods for measuring the functional activity of
antibodies against malaria blood stage antigens. Am J Trop Med Hyg 2006; 75:
437442.
38 Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P.
Antibodies that protect humans against Plasmodium falciparum blood stages do noton their own inhibit parasite growth and invasion in vitro, but act in cooperation with
monocytes. J Exp Med 1990; 172: 16331641.
39 Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the
monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual
blood stages. J Exp Med 1995; 182: 409418.
40 Diggs CL, Osler AG. Humoral immunity in rodent malaria. III: studies on the site of
antibody action. J Immunol 1975; 114: 12431247.
41 Mitchell GH, Butcher GA, Voller A, Cohen S. The effect of human immune IgG on the
in vitro development of Plasmodium falciparum. Parasitology 1976; 72: 149162.
42 Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A et al. A recombinant
blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts
selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.
J Infect Dis 2002; 185: 820827.
43 Ling IT, Ogun SA, Holder AA. Immunization against malaria with a recombinant
protein. Parasite Immunol1994; 16: 6367.
44 Perera KL, Handunnetti SM, Holm I, Longacre S, Mendis K. Baculovirus merozoite
surface protein 1 C-terminal recombinant antigens are highly protective in a natural
primate model for human Plasmodium vivax malaria. Infect Immun 1998; 66:
15001506.
45 Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to
apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-
specific epitopes. Infect Immun 1996; 64: 33103317.
46 Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, Sulzer AJ et al.
Protective immunity induced in squirrel monkeys with recombinant apical membrane
antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 1994; 51: 711719.
47 Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P et al.
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAPagainst malaria infection in Gambian adults. PLoS Med 2004; 1: e33.
48 Bejon P, Mwacharo J, Kai O, Mwangi T, Milligan P, Todryk S et al. A phase 2b
randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP
among children in Kenya. PLoS Clin Trials 2006; 1: e29.
49 Feachem R, Sabot O. A new global malaria eradication strategy. Lancet 2008; 371:
16331635.
50 World Health Organization. The Role Back Malaria Partnership. Global Malaria Action
Plan. WHO: Geneva, 2008.
51 Volkman SK, Hartl DL, Wirth DF, Nielsen KM, Choi M, Batalov S et al. Excess
polymorphisms in genes for membrane proteins in Plasmodium falciparum. Science
2002; 298: 216218.
52 Polley SD, Conway DJ. Strong diversifying selection on domains of the Plasmodium
falciparum apical membrane antigen 1 gene. Genetics 2001; 158: 15051512.
53 Miller LH, Roberts T, Shahabuddin M, McCutchan TF. Analysis of sequence diversity
in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem
Parasitol 1993; 59: 114.
54 Smythe JA, Peterson MG, Coppel RL, Saul AJ, Kemp DJ, Anders RF. Structural
diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum.
Mol Biochem Parasitol 1990; 39: 227234.55 Cortes A. Switching Plasmodium falciparumgenes on and off for erythrocyte invasion.
Trends Parasitol 2008; 24: 517524.
56 Persson KE, McCallum FJ, Reiling L, Lister NA, Stubbs J, Cowman AF et al. Variation
in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion
of human inhibitory antibodies. J Clin Invest 2008; 118: 342351.
57 Baum J, Maier AG, Good RT, Simpson KM, Cowman AF. Invasion by P. falciparum
merozoites suggestsa hierarchy ofmolecular interactions. PLoSPathog2005; 1: e37.
58 Guevara Patino JA, Holder AA, McBride JS, Blackman MJ. Antibodies that inhibit
malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked
by naturally acquired human antibodies. J Exp Med 1997; 186: 16891699.
59 Miura K, Zhou H, Moretz SE, Diouf A,TheraMA, Dolo A etal. Comparison of biological
activity of human anti-apical membrane antigen-1 antibodies induced by natural
infection and vaccination. J Immunol 2008; 181: 87768783.
60 Stanisic DI, Martin LB, GattonML, Good MF. Inhibition of 19-kDaC-terminal region of
merozoite surface protein-1-specific antibody responses in neonatal pups by mater-
nally derived 19-kDa C-terminal region of merozoite surface protein-1-specific
antibodies but not whole parasite-specific antibodies. J Immunol 2004; 172:
55705581.61 Wykes MN, Good MF. What really happens to dendritic cells during malaria? Nature
Rev 2008; 6: 864870.
62 Wykes MN, Liu XQ, Beattie L, Stanisic DI, Stacey KJ, Smyth MJ et al. Plasmodium
strain determines dendritic cell function essential for survival from malaria. PLoS
Pathog 2007; 3: e96.
63 Xiao L, Rafi-Janajreh A, Patterson P, Zhou Z, Lal AA. Adjuvants and malaria vaccine
development. Chem Immunol 2002; 80: 343365.
64 Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL et al. Protection of
humans against malaria by immunization with radiation-attenuated Plasmodium
falciparum sporozoites. J Infect Dis 2002; 185: 11551164.
65 Collins WE, Jeffery GM. A retrospective examination of secondary sporozoite- and
trophozoite- induced infections with Plasmodium falciparum: development of para-
sitologic and clinical immunity following secondary infection. Am J Trop Med Hyg
1999; 61: 2035.
66 Brown KN, Brown IN. Immunity to malaria: antigenic variation in chronic infections of
Plasmodium knowlesi. Nature 1965; 208: 12861288.
67 Jones TR, Obaldia III N, Gramzinski RA, Hoffman SL. Repeated infection of Aotus
monkeys with Plasmodium falciparum induces protection against subsequent chal-
lenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg2000; 62: 675680.
68 Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N et al.
Immunity to malaria after administration of ultra-low doses of red cells infected with
Plasmodium falciparum. Lancet 2002; 360: 610617.
69 Renia L, Gruner AC, Mauduit M, Snounou G. Vaccination against malaria with live
parasites. Expert Rev Vaccines 2006; 5: 473481.
70 Wykes M, Good MF. A case for whole-parasite malaria vaccines. Int J Parasitol 2007;
37: 705712.
71 Pinzon-Charry A, Good MF. Malaria vaccines: the case for a whole-organism approach.
Expert Opin Biol Ther 2008; 8: 441448.
72 Patarroyo ME, Patarroyo MA. Emerging rules for subunit-based, multiantigenic,
multistage chemically synthesized vaccines. Acc Chem Res 2008; 41: 377386.
73 Corradin G, Spertini F, Verdini A. Medicinal application of long synthetic peptide
technology. Expert Opin Biol Ther 2004; 4: 16291639.
74 Satterthwait AC, Chiang LC, Arrhenius T, Cabezas E, Zavala F, Dyson HJ et al. The
conformational restriction of synthetic vaccines for malaria. Bull World Health Organ
1990; 68: 1725.
Blood-stage vaccines against malariaJS Richards and JG Beeson
386
mmunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
11/14
75 Jackson DC, Purcell AW, Fitzmaurice CJ, Zeng W, Hart DN. The central role played by
peptides in the immune response and the design of peptide-based vaccines against
infectious diseases and cancer. Curr Drug Targets 2002; 3: 175196.
76 Riley EM, Olerup O, Bennett S, Rowe P, Allen SJ, Blackman MJ et al. MHC and
malaria: the relationship between HLA class II alleles and immune responses to
Plasmodium falciparum. Int Immunol 1992; 4: 10551063.
77 Doolan DL, Hoffman SL. DNA-based vaccines against malaria: status and promise of
the multi-stage malaria DNA vaccine operation. Int J Parasitol 2001; 31: 753762.
78 Dunachie SJ, Hill AV. Prime-boost strategies for malaria vaccine development. J Exp
Biol 2003; 206: 37713779.79 Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization
strategies for malaria. Immunol Rev 2004; 199: 126143.
80 Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ et al. Viral vectors for
malaria vaccine development. Vaccine 2007; 25: 25672574.
81 Reyes-Sandoval A, Harty JT, Todryk SM. Viral vector vaccines make memory T cells
against malaria. Immunology 2007; 121: 158165.
82 Tyagi RK, Sharma PK, Vyas SP, Mehta A. Various carrier system(s)-mediated genetic
vaccination strategies against malaria. Expert Rev Vaccines 2008; 7: 499520.
83 Sanders PR, Cantin GT, Greenbaum DC, Gilson PR, Nebl T, Moritz RL et al.
Identification of protein complexes in detergent-resistant membranes of Plasmodium
falciparum schizonts. Mol Biochem Parasitol 2007; 154: 148157.
84 Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, Carucci DJ et al. Distinct
protein classes including novel merozoite surface antigens in Raft-like membranes of
Plasmodium falciparum. J Biol Chem 2005; 280: 4016940176.
85 Mu J, Awadalla P, Duan J, McGee KM, Keebler J, Seydel K et al. Genome-wide
variation and identification of vaccine targets in the Plasmodium falciparum genome.
Nature genet 2007; 39: 126130.
86 Doolan DL, Aguiar JC, Weiss WR, Sette A, Felgner PL, Regis DP et al. Utilization of
genomic sequence information to develop malaria vaccines. J Exp Biol 2003; 206:37893802.
87 Winzeler EA. Applied systems biology and malaria. Nature Rev 2006; 4: 145151.
88 Winzeler EA. Malaria research in the post-genomic era. Nature2008; 455: 751756.
89 Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD et al. A
proteomic view of the Plasmodium falciparum life cycle. Nature 2002; 419:
520526.
90 Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006;
124: 755766.
91 Gerold P, Schofield L,Blackman MJ, Holder AA, Schwarz RT. Structural analysis of the
glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1
and -2 of Plasmodium falciparum. Mol Biochem Parasitol 1996; 75: 131143.
92 Holder AA, Freeman RR. Immunization against blood-stage rodent malaria using
purified parasite antigens. Nature 1981; 294: 361364.
93 Blackman MJ, Ling IT, Nicholls SC, Holder AA. Proteolytic processing of the
Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound
fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol
1991; 49: 2933.
94 Chitarra V, Holm I, Bentley GA, Petres S, Longacre S. The crystal structure ofC-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria
vaccine candidate. Mol Cell 1999; 3: 457464.
95 Pizarro JC, Chitarra V, Verger D, Holm I, Petres S, Dartevelle S et al. Crystal structure
of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite
surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J Mol
Biol 2003; 328: 10911103.
96 Goel VK, Li X, Chen H, Liu SC, Chishti AH, Oh SS. Band 3 is a host receptor binding
merozoite surface protein 1 during the Plasmodium falciparum invasion of erythro-
cytes. Proc Natl Acad Sci USA 2003; 100: 51645169.
97 Li X, Chen H, Oo TH, Daly TM, Bergman LW, Liu SC et al. A co-ligand complex anchors
Plasmodium falciparummerozoites to the erythrocyte invasion receptor band 3. J Biol
Chem 2004; 279: 57655771.
98 Polley SD, Tetteh KK, Cavanagh DR, Pearce RJ, Lloyd JM, Bojang KA et al. Repeat
sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are
targets of antibodies associated with protection from malaria. Infect Immun 2003;
71: 18331842.
99 Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B et al. Naturally
acquired cellular and humoral immune responses to the major merozoite surface
antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malariamorbidity. Parasite Immunol1992; 14: 321337.
100Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL et al.
A longitudinal investigation of IgG and IgM antibody responses to the merozoite
surface protein-1 19-kiloDalton domain of Plasmodium falciparumin pregnantwomen
and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med
Hyg 1998; 58: 211219.
101Egan AF, Burghaus P, Druilhe P, Holder AA, Riley EM. Human antibodies to the 19 kDa
C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit
parasite growth in vitro. Parasite Immunol1999; 21: 133139.
102Dodoo D, Theander TG, Kurtzhals JA, Koram K, Riley E, Akanmori BD et al. Levels of
antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in
Ghanaian children are not associated with protection from clinical malaria. Infect
Immun1999; 67: 21312137.
103ODonnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF et al.
Antibodies against merozoite surface protein (MSP)-1(19) are a major component of
the invasion-inhibitory response in individuals immune to malaria. J Exp Med 2001;
193: 14031412.
104Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA. Antibodies inhibit the protease-
mediated processing of a malaria merozoite surface protein. J Exp Med 1994; 180:
389393.
105Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and
immunological characterization of bacterially expressed and refolded Plasmodium
falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun2003;
71: 67666774.
106Daly TM, Long CA. A recombinant 15-kilodalton carboxyl-terminal fragment of
Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective
immune response in mice. Infect Immun 1993; 61: 24622467.107Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA et al.
Immunogenicity and in vivoefficacy of recombinant Plasmodium falciparummerozoite
surface protein-1 in Aotus monkeys. Mol Med 1995; 1: 325332.
108Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF et al. Phase I
safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1
asexual blood stage vaccine. Vaccine 2006; 24: 30093017.
109Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M et al. Phase 1
randomized double-blind safety and immunogenicity trial of Plasmodium falciparum
malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in
western Kenya. Vaccine 2007; 25: 176184.
110Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A et al. Safety and
allele-specific immunogenicity of a malariavaccine in Malian adults: results of a phase
I randomized trial. PLoS Clin Trials 2006; 1: e34.
111Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F et al. Blood stage
malaria vaccine eliciting high antigen-specific antibody concentrations confers no
protection to young children in western Kenya. PLoS ONE 2009; 4: e4708.
112Malkin E, Long CA, Stowers AW, Zou L, Singh S, Macdonald NJ et al. Phase 1 study of
two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum
malaria. PLoS Clin Trials 2007; 2: e12.113Pan W, Huang D, Zhang Q, Qu L, Zhang D, Zhang X et al. Fusion of two malaria vaccine
candidate antigens enhances product yield, immunogenicity, and antibody-mediated
inhibition of parasite growth in vitro. J Immunol 2004; 172: 61676174.
114Langermans JA, Hensmann M, van Gijlswijk M, Zhang D, Pan W, Giersing BK et al.
Preclinical evaluation of a chimeric malaria vaccine candidate in montanide ISA
720((R)): immunogenicity and safety in Rhesus macaques. Human Vaccin 2006; 2:
222226.
115Hu J, Chen Z, Gu J, Wan M, Shen Q, Kieny MP et al. Safety and immunogenicity of a
malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated
in montanide ISA 720 in healthy adults. PLoS ONE 2008; 3: e1952.
116Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z et al. A Phase 1 trial of PfCP2.9: An AMA1/
MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
Vaccine 2008; 26: 68646873.
117Valderrama-Aguirre A, Quintero G, Gomez A, Castellanos A, Perez Y, Mendez F et al.
Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1
PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 2005; 73: 1624.
118Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN et al. High
levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparumare associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006;
24: 42334246.
119Sturchler D, Berger R, Rudin C, Just M, Saul A, Rzepczyk C et al. Safety, immuno-
genicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-
stage combination vaccine in Swiss adults. Am J Trop Med Hyg1995; 53: 423431.
120Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D et al. Human phase I
vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide
ISA720 adjuvant. Vaccine 1999; 17: 31453159.
121Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N et al. Effect of
vaccination with 3 recombinant asexual-stage malaria antigens on initial growth
rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000; 18:
19251931.
122Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D et al. Safety and
immunogenicity of a three-component blood-stage malaria vaccine in adults living
in an endemic area of Papua New Guinea [In Process Citation]. Vaccine 2000; 18:
25042511.
123Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K et al. Safety and
immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2,
RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine2003; 22: 3041.
124Fluck C, Schopflin S, Smith T, Genton B, Alpers MP, Beck HP et al. Effect of the
malaria vaccine Combination B on merozoite surface antigen 2 diversity. Infect Genet
Evol 2007; 7: 4451.
125Fluck C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP et al. Strain-specific humoral
response to a polymorphic malaria vaccine. Infect Immun 2004; 72: 63006305.
126 Mills KE, Pearce JA, Crabb BS, Cowman AF. Truncation of merozoite surface protein 3
disrupts its trafficking and that of acidic-basic repeat protein to the surface of
Plasmodium falciparum merozoites. Mol Microbiol 2002; 43: 14011411.
127McColl DJ, Anders RF. Conservation of structural motifs and antigenic diversity in the
Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol
1997; 90: 2131.
128McColl DJ, Silva A, Foley M, Kun JF, Favaloro JM, Thompson JK et al. Molecular
variation in a novel polymorphic antigen associated with Plasmodium falciparum
merozoites. Mol Biochem Parasitol 1994; 68: 5367.
129Escalante AA, Lal AA, Ayala FJ. Genetic polymorphism and natural selection in the
malaria parasite Plasmodium falciparum. Genetics 1998; 149: 189202.
Blood-stage vaccines against malariaJS Richards and JG Beeson
387
Immunology and Cell Biology
-
8/2/2019 Review on Blood Stage Vaccine Against Malarai
12/14
130Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection
against clinical malaria and antibodies to merozoite surface antigens in an area of
hyperendemicity in Myanmar: complementarity between responses to merozoite sur-
face protein3 and the 220-kilodalton glutamate-rich protein. InfectImmun2004; 72:
247252.
131Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, Singh S et al. A malaria vaccine
that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med
2005; 2: e344.
132Audran R, Cachat M, Lurati F, Soe S, LeroyO, Corradin G et al. Phase I malaria vaccine
trial with a long synthetic peptide derived from the merozoite surface protein 3antigen. Infect Immun 2005; 73: 80178026.
133Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M et al.
Merozoite surface protein-3: a malaria protein inducing antibodies that promote
Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994;
84: 15941602.
134Singh S, Soe S, Mejia JP, Roussilhon C, Theisen M, Corradin G et al. Identification of a
conserved region of Plasmodium falciparum MSP3 targeted by biologically active
antibodies to improve vaccine design. J Infect Dis 2004; 190: 10101018.
135Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A et al. Safety and
immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long
synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult
males in Burkina Faso, West Africa. Vaccine 2007; 25: 27232732.
136Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H et al.
A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus
lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004;
22: 11881198.
137Remarque EJ, Faber BW, Kocken CH, Thomas AW. Apical membrane antigen 1: a
malaria vaccine candidate in review. Trends Parasitol 2008; 24: 7484.138Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C,
Hackett F et al. Crystal structure of the malaria vaccine candidate apical membrane
antigen 1. Science 2005; 308: 408411.
139Alexander DL, Arastu-Kapur S, Dubremetz JF, Boothroyd JC. Plasmodium falciparum
AMA1 binds a rhoptry neck protein homologous to TgRON4, a component of the
moving junction in Toxoplasma gondii. Eukaryot cell 2006; 5: 11691173.
140Marshall VM, Zhang L, Anders RF, Coppel RL. Diversity of the vaccine candidate AMA-
1 of Plasmodium falciparum. Mol Biochem Parasitol 1996; 77: 109113.
141Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A et al. In vitro studies with
recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production
and activity of an AMA1 vaccine and generation of a multiallelic response. Infect
Immun 2002; 70: 69486960.
142Escalante AA, Grebert HM, Chaiyaroj SC, Magris M, Biswas S, Nahlen BL et al.
Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of
Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol Biochem Parasitol
2001; 113: 279287.
143Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders RF. Geographical
structure of diversity and differences between symptomatic and asymptomatic infec-
tions for Plasmodium falciparum vaccine candidate AMA1. Infect Immun 2003; 71:
14161426.
144Polley SD, Mwangi T, Kocken CH, Tho
top related